ERBB3 and breast cancer: The U31402-A-J101 study is a phase I/II trial to assess the maximum tolerated dose (in the dose-escalation part) and the safety and efficacy (in the dose expansion part) of HER3-DXd in patients with previously treated HER3 expressing BC (28).